European Pharmaceutical Review

DECEMBER 1, 2022

According to GlobalData’s recent report , a total of five marketed messenger RNA (mRNA) non-vaccine products by 2028 will generate over $2 billion, generated by the approval of pipeline agents. billion during 2028.

Vaccines 93

Vaccines Immunization 93

STAT

JANUARY 8, 2024

Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs for $680 million. That could come as soon as 2028. Keytruda, a PD-(L)1 inhibitor, works by turning off a “brake” on T cells, allowing roving immune cells to attack tumors.

Immunization 109

Immunization 109

Pharmaceutical Technology

MAY 26, 2023

was powered by the advent of immune-checkpoint inhibitors, added Chalk. These figures are only expected to grow in the coming years, with sales forecasted to reach over $150 billion by 2028. Checkpoint modulators, cytokines and oncolytic viruses are also considered as part of the overall immune-oncology field.

Immunization 105

Immunization Vaccines Compounding Insurance 105

Pharmaceutical Technology

AUGUST 16, 2022

Enhertu has already achieved regulatory approval as a second-line therapy for metastatic or recurrent HER2-positive breast cancer, as well as HER2-positive gastric or gastroesophageal junction adenocarcinoma, with annual sales for these indications alone expected to exceed $1.3bn by 2028.

Chemotherapy 59

Chemotherapy Immunization FDA 59

European Pharmaceutical Review

NOVEMBER 1, 2023

Pneumococcal Vaccines Market Size & Share Analysis – Growth Trends & Forecasts 2023-2028. The current state of immunization against Gram-negative bacteria in children: a review of the literature. 2022 [cited May2023], Available from: [link] Murray CJ, Ikuta KS, Sharara F, et al. The Lancet. 2022; 399(10325): 629–55.

Vaccines 101

Vaccines Immunization 101

Pharmaceutical Technology

OCTOBER 28, 2022

What’s more, VAX-24 achieved a higher immune response to 16 of the 20 serotypes it shares with Prevnar 20. billion and $812 million in 2028. On October 26, Vaxcyte stated that this offering was expected to yield approximately $600 million in gross proceeds The company now has a market cap of $2.47 Further plans in the making.

Vaccines 64

Vaccines FDA Immunization 64

Roots Analysis

OCTOBER 4, 2023

They are designed to recognize and bind to two specific molecules, such as a tumor cell and an immune cell, or two different parts of the same molecule. Bispecific antibodies are a type of antibody that can bind to two different targets at the same time.

Chemotherapy 40

Chemotherapy Immunization FDA 40